INT26863

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.09
First Reported 1989
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 2.67
Pain Relevance 2.23

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Vms1 (Mus musculus)
Pain Link Frequency Relevance Heat
transdermal 21 100.00 Very High Very High Very High
Enkephalin 14 99.20 Very High Very High Very High
narcan 4 96.88 Very High Very High Very High
MU agonist 2 86.00 High High
depression 41 83.40 Quite High
Serotonin 16 83.12 Quite High
Neurotransmitter 7 82.72 Quite High
Opioid 2 74.00 Quite High
cva 1 71.72 Quite High
Bioavailability 1 62.84 Quite High
Disease Link Frequency Relevance Heat
Cardiovascular Disease 3 99.68 Very High Very High Very High
Endometriosis (extended) 170 99.32 Very High Very High Very High
Osteoporosis 13 97.68 Very High Very High Very High
Chronic Disease 3 95.20 Very High Very High Very High
Obesity 21 85.92 High High
Anxiety Disorder 18 84.84 Quite High
Cognitive Disorder 47 83.44 Quite High
Depression 48 83.40 Quite High
Adhesions 1 82.52 Quite High
Frailty 6 81.92 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Presented here are summaries of the clinical trials evaluating the effects of transdermal estrogen spray and estradiol topical emulsion on VMS associated with menopause.
Regulation (effects) of VMS associated with transdermal and endometriosis (extended)
1) Confidence 0.09 Published 2010 Journal Int J Gen Med Section Body Doc Link PMC2880349 Disease Relevance 0.49 Pain Relevance 0.48
VMS-related effects on QOL
Regulation (effects) of VMS
2) Confidence 0.06 Published 2005 Journal Health Qual Life Outcomes Section Body Doc Link PMC1190205 Disease Relevance 1.12 Pain Relevance 0.04
Effects of associated VMS on QOL
Regulation (Effects) of VMS
3) Confidence 0.06 Published 2005 Journal Health Qual Life Outcomes Section Body Doc Link PMC1190205 Disease Relevance 0.37 Pain Relevance 0.08
[D-Ala2,D-Leu5]enkephalin (DADLE) (10 microM) had no significant effect on the transepithelial potential difference (Vms), Isc, delta Vms and delta Isc.
Neg (no) Regulation (effect) of Vms associated with enkephalin
4) Confidence 0.04 Published 1989 Journal J. Pharm. Pharmacol. Section Abstract Doc Link 2570860 Disease Relevance 0 Pain Relevance 0.73
[D-Ala2,D-Leu5]enkephalin (DADLE) (10 microM) had no significant effect on the transepithelial potential difference (Vms), Isc, delta Vms and delta Isc.
Neg (no) Regulation (effect) of Vms associated with enkephalin
5) Confidence 0.04 Published 1989 Journal J. Pharm. Pharmacol. Section Abstract Doc Link 2570860 Disease Relevance 0 Pain Relevance 0.72
The development of therapies that specifically target VMS may provide high efficacy and reduced risk of serious and potentially costly adverse events, thus increasing the overall cost-effectiveness of therapy.


Regulation (target) of VMS
6) Confidence 0.03 Published 2005 Journal Health Qual Life Outcomes Section Body Doc Link PMC1190205 Disease Relevance 0.42 Pain Relevance 0.12
In the present study, we included more subjects (exposed, 162; referent, 151), with higher initial outbreak exposure [mean of 78.3 ppb (ng/g)], sex-specific neurocognitive effects, and a significant dose response in the ADS, VMS, and VMR in the exposed females.
Regulation (response) of VMS
7) Confidence 0.01 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2235226 Disease Relevance 0.28 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox